Bo Yang1, Ji Wang2, Li-Li Cai3, Hong-Li Zhu1, Rui-Li Yu4, Xiao-Hua Chi5, Xue-Chun Lu6. 1. Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China. 2. Department of Cadre Health Care, Chinese PLA Navy General Hospital, Beijing, China. 3. Department of Geriatric Laboratory Medicine, Chinese PLA General Hospital, Beijing, China. 4. Institute of Otorhinolaryngology, Chinese PLA General Hospital, Beijing, China. 5. Department of Pharmacy, the Second Artillery General Hospital, Beijing, China. 6. Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China. Electronic address: luxuechun@126.com.
Abstract
BACKGROUND AIMS: Currently available treatment methods for advanced plasmacytoma include surgery, chemotherapy, radiotherapy, immunomodulatory agents, hematopoietic stem cell transplantation and donor lymphocyte infusion. We report a case of advanced refractory multiple solitary plasmacytomas in a 68-year-old Asian man with multiple bone lesions, in whom autologous cytokine-induced killer (CIK) cells were administered in an effort to eliminate residual tumor lesions. METHODS: CIK cells were infused monthly for 21 courses. RESULTS: The patient has survived 63 months since the first hospital visit without disease progression for 40 months. CONCLUSIONS: This case represents the first report of autologous CIK cell immunotherapy used successfully to suppress multiple solitary plasmacytomas and resolve bone lesions.
BACKGROUND AIMS: Currently available treatment methods for advanced plasmacytoma include surgery, chemotherapy, radiotherapy, immunomodulatory agents, hematopoietic stem cell transplantation and donor lymphocyte infusion. We report a case of advanced refractory multiple solitary plasmacytomas in a 68-year-old Asian man with multiple bone lesions, in whom autologous cytokine-induced killer (CIK) cells were administered in an effort to eliminate residual tumor lesions. METHODS: CIK cells were infused monthly for 21 courses. RESULTS: The patient has survived 63 months since the first hospital visit without disease progression for 40 months. CONCLUSIONS: This case represents the first report of autologous CIK cell immunotherapy used successfully to suppress multiple solitary plasmacytomas and resolve bone lesions.
Authors: Leonard Christopher Schmeel; Frederic Carsten Schmeel; Christoph Coch; Ingo G H Schmidt-Wolf Journal: J Cancer Res Clin Oncol Date: 2014-11-08 Impact factor: 4.553
Authors: Frederic Carsten Schmeel; Leonard Christopher Schmeel; Sanna-Marie Gast; Ingo G H Schmidt-Wolf Journal: Int J Mol Sci Date: 2014-08-21 Impact factor: 5.923